Expression of CD133 in acute leukemia

Medical Oncology

Volumn 30, Issue 2, 2013, Pages

  Tolba, Fetnat M ^a   Foda, Mona E ^a   Kamal, Howyda M ^a   Elshabrawy, Deena A ^a  

^a BENHA UNIVERSITY   (Egypt)

Author keywords

ALL; AML; CD133; Flow cytometry

Indexed keywords

ANTINEOPLASTIC AGENT; CD133 ANTIGEN; CD3 ANTIGEN; CD34 ANTIGEN; CD7 ANTIGEN; HLA DR ANTIGEN; MICROSOMAL AMINOPEPTIDASE; GLYCOPROTEIN; LEUKOCYTE ANTIGEN; PEPTIDE; TUMOR MARKER;

ACUTE GRANULOCYTIC LEUKEMIA; ACUTE LYMPHOBLASTIC LEUKEMIA; ADOLESCENT; ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; BLAST CELL; CANCER CHEMOTHERAPY; CANCER PATIENT; CANCER PROGNOSIS; CANCER REGRESSION; CANCER RESISTANCE; CANCER THERAPY; CHILD; FEMALE; FLOW CYTOMETRY; FOLLOW UP; HUMAN; INFANT; MAJOR CLINICAL STUDY; MALE; PRESCHOOL CHILD; PRIORITY JOURNAL; SCHOOL CHILD; TREATMENT OUTCOME; TREATMENT RESPONSE; BIOSYNTHESIS; GENE EXPRESSION REGULATION; GENETICS; KAPLAN MEIER METHOD; METABOLISM; MIDDLE AGED; MORTALITY; PROGNOSIS;

ADOLESCENT; ADULT; AGED; ANTIGENS, CD; CHILD; CHILD, PRESCHOOL; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GLYCOPROTEINS; HUMANS; INFANT; KAPLAN-MEIER ESTIMATE; LEUKEMIA, MYELOID, ACUTE; MALE; MIDDLE AGED; PEPTIDES; PRECURSOR CELL LYMPHOBLASTIC LEUKEMIA-LYMPHOMA; PROGNOSIS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84875353320     PISSN: 13570560     EISSN: 1559131X     Source Type: Journal    
DOI: 10.1007/s12032-013-0527-6     Document Type: Article

References (31)

1. Hong D, Gupta R, Ancliff P, Azberger A, et al. Initiating and cancer propagating cell in Tel-AML1 associated childhood leukemia. Science. 2008;319:336-9.
2. Cobaleda C, Gutierrez-Cianca N, Perez-Losada J, Flores T, et al. A primitive hematopoietic cell is the target for the leukemia transformation in human Philadelphia-positive acute lymphoblastic leukemia. Blood. 2000;95:1007-13.
3. Plasschaert SL, Kamps WA, Vellenga E, De Vries EG, et al. Prognosis in childhood and adult acute lymphoblastic leukemia: a question of maturation? Cancer Treat Rev. 2004;30:37-51.
4. Cox CV, Blair A. A primitive cell origin for B-cell precursors ALL. Stem Cell Rev. 2005;1(3):189-96.
5. Toren A, Bielorai Y, Jacob-Hirsch J. CD133-positive hematopoietic stem cell "stemness" genes contain many genes mutated or abnormally expressed in leukemia. Stem cells. 2006;23:1142-53.
6. Wuchter C, Ratel R, Spahn G, Schoch C, Harbott J. Impact of CD133 (AC133) and CD90 expression analysis for acute leukemia immunophenotyping. Haematologica. 2001;86:154-61.
7. Miraglia S, Godfrey W, Yin AH, Atkins K, et al. A novel five transmembrane hematopoietic stem cell antigen: isolation, characterization and molecular cloning. Blood. 1997;90:5013-21.
8. Horn PA, Tesch H, Staib P(. Expression of CD133, a novel hematopoietic precursor antigen, on acute myeloid leukemia cell line. Blood. 1999;93:1435-7.
9. Yamashita Y, Ohashi J, Hirai Y, Mano H. Gene expression profiles of CD133 positive fractions predict the survival of individuals with acute myeloid leukemia. Cancer Genomics Proteomics. 2006;3(3):169.
10. + B-cell precursors. Blood. 2002;94:832-3.
11. Corbeil D, Roper K, Hellwig A, et al. The human CD133 hematopoietic stem cell antigen is also expressed in epithelial cells and targeted to plasma membrane protrusions. I Biol Cbem. 2003;275:5512-20.
12. + leukemic cell line: MUTZ-2. Blood. 2001;92:4485-7.
13. Greer J, Baer M, Kinnery M. Acute myelogenous leukemia. In: Lee G, Foester J, Leukens J, Pareskerva F, Greer J, Rogers G, editors. Wintrobe's clinical Hematology. 12th ed. Philadelphia: Lippincott Williams and Wilkins; 2009. p. 2045-62.
14. Tangen JM, Fløisand Y, Foss-Abrahamsen J, et al. Survival in adults with acute myelogenous leukemia. Tidsskr Nor Laegeforen. 2008;128(10):1164-7.
15. Guenova M, Balatzenko G. CD133-2 (AC141) expression analysis in acute leukemia immunophenotyping in correlation to CD34 and P-glycoprotein. Hematology. 2008;13(3):137-41.
16. Elgendi HM, Mekawy MA, Abdel Waohab SE, Tawfik LM, et al. AC133 Expression in Egyptian children with Acute Leukemia: Impact on treatment response and disease outcome. J Pediatr Hematol Oncol. 2010;32:286-93.
17. Raspadori D, Lauria F, Ventura MA, Rondelli DA, et al. Incidence and prognostic relevance of CD34 expression in acute myeloblastic leukemia: analysis of 141 cases. Leuk Res. 1997;21(7):603-7.
18. Pellacani D, Packer RJ, Frame FM, et al. Regulation of the stem cell marker CD133 is independent of promoter hypermethylation in human epithelial differentiation and cancer. Mole Cancer. 2011;10:94. doi: 10.1186/1476-4598-10- 94.
19. Lee ST, Jang HJ, Min YH, Hahn JS, Ko YW. AC133 antigen as a prognostic factor in acute leukemia. Leuk Res. 2001;25:757-61.
20. Vercauteren SM, Sutherland HJ. CD133 (AC133) expression on AML cells and progenitors. Cytotherapy. 2001;3(6):449-59.
21. Zhou Y, Li Q, Meng HX, Wang YF, et al. The expression and clinical significance of early differentiation antigens in acute leukemia. Zhonghua Nei Ke Za Zhi. 2005;44(1):46-9.
22. Wang W, Wang HY, Zhao HX, Cui ZG, Li GL. Expression of CD133 in bone marrow cells of patients with leukemia and myelodysplastic syndrome. Zhongguo Shi Yan Xue Ye Xue Za Zhi. 2007;15(3):470-3.
23. Fauth F, Weidmann E, Martin H, Schneider B, et al. AC133 Expression on acute myeloid leukemia blasts: correlation to FAB and to CD34 expression and possible implications for peripheral blood progenitor cell purging in AML. Leuk Res. 2001;25:191-6.
24. Kim JH, Cho HI, Kim EC, Ko EK, et al. A study on 289 consecutive Korean patients with acute leukaemias revealed fluorescence in situ hybridization detects the MLL translocation without cytogenetic initially and during follow-up. Br J Haematol. 2002;119(4):930-9.
25. Zhou Y, Meng HX, Yu Z, Li Q, et al. The expression of CD133 in acute leukemia and its clinical significance. Zhonghua Xue Ye Xue Za Zhi. 2004;25(7):401-4.
26. Taguchi J, Miyazaki Y, Tsutsumi C, et al. Expression of the myeloperoxidase gene in AC133 positive leukemia cells relates to the prognosis of acute myeloid leukemia. Leuk Res. 2006;30(9):1105.
27. Cox CV, Diamanti P, Evely RS. Expression of CD133 on leukemia- initiating cells in childhood ALL. Blood. 2009;113:3287-96.
28. Langer C, Radmacher MD, Ruppert AS. High BAALC expression associates with other molecular prognostic markers, poor outcome, and a distinct gene- expression signature in cytogenetically normal patients younger than 60 years with acute myeloid leukemia: a Cancer and Leukemia Group B (CALGB) study. Blood. 2008;111:5371-9.
29. Lichtman SM, Hollis D, Miller AA. Prospective evaluation of the relationship of patient age and clinical pharmacology: cancer and Leukemia Group B (CALGB 9762). J Clin Oncol. 2006;24:1846-51.
30. Christian W, Richard R, Gunther S, Claudia S, et al. Impact of CD133 (AC133) and CD90 expression analysis for acute leukemia immunophenotyping. Haematologica. 2001;86:154-61.
31. Lichtman MA, Liesveld JL. Acute Myelogenous leukemia. In: Lichtman MA, Kipps TJ, Kaushansky K, Beutler E, Seligsohn U Prchal J editors. William′s Hematology. 7th ed. USA; McGraw-Hill companies: (2006). p. 1183.